INM
InMed Pharmaceuticals Inc.
$1.51
-4.43%
$4.2M
No data for this timeframe.
Vol
Market Cap$4.2M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$30.3K
Inst. Activity1 buys / 0 sells
Insider Activity10B / 0S
Insider Net $$465.3K
Reddit Sentiment50° Neutral
SEC Reports10
Recent Activity
Jun 11, 2026
SEC
Two 10% owners (Vivo Opportunity, LLC and ADAR1 Capital Management, LLC) purchased a combined $189K of INM stock in an 8
CLUSTER — Impact 7/10
Jun 10, 2026
SEC
InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, closing a delisting notice re
8-K — Impact 4/10
Jun 8, 2026
Insider
Vivo Opportunity, LLC bought 29,518 shares
10%+ Owner @ $1.52 ($44.9K)
Jun 5, 2026
Insider
Vivo Opportunity, LLC bought 49,966 shares
10%+ Owner @ $1.57 ($78.4K)
Jun 4, 2026
Insider
Vivo Opportunity, LLC bought 6,125 shares
10%+ Owner @ $1.57 ($9.6K)
May 19, 2026
SEC
InMed Pharmaceuticals (INM) entered into a definitive reverse merger agreement with Mentari Therapeutics, where Mentari
425 — Impact 7/10
Inst.
UBS Group AG — ADD
7,762 shares ($25.2K)
Inst.
UBS Group AG — TRIM
6,106 shares ($12.6K)
Analyst Ratings
0Strong Buy
0Buy
3Hold
4Sell
1Strong Sell
Latest Reports
BULLISH
CLUSTER
7/10
Two 10% owners (Vivo Opportunity, LLC and ADAR1 Capital Management, LLC) purchased a combined $189K of INM stock in an 8
Jun 11, 2026
NEUTRAL
8-K
4/10
InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, closing a delisting notice re
Jun 10, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| CITADEL ADVISORS LLC | $30.3K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Vivo Opportunity, | BUY | $44.9K |
| Jun 5, 2026 | Vivo Opportunity, | BUY | $78.4K |
| Jun 4, 2026 | Vivo Opportunity, | BUY | $9.6K |
| Jun 3, 2026 | Vivo Opportunity, | BUY | $11.0K |
| Jun 2, 2026 | Vivo Opportunity, | BUY | $31.5K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
1 institutional holders with $30.3K total value (46,973 shares) as of 2026-Q1. Top holders: CITADEL.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 46,973 | $30.3K | 100.0% | DOUBLED +368.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | ADD | 6,106 | 7,762 | +27.1% | $25.2K | 2025-Q2 |
| UBS Group AG | TRIM | 10,408 | 6,106 | -41.3% | $12.6K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 12,097 | 56,666 | +368.4% | $13.3K | 2024-Q3 |
| HRT FINANCIAL LP | DOUBLED | 15,996 | 38,369 | +139.9% | $8.00 | 2024-Q3 |
2 unique insiders with 10 transactions. Net insider value: $465.3K ($465.3K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 29,518 | $1.52 | $44.9K |
| Jun 5, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 49,966 | $1.57 | $78.4K |
| Jun 4, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 6,125 | $1.57 | $9.6K |
| Jun 3, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 7,069 | $1.55 | $11.0K |
| Jun 2, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 20,753 | $1.52 | $31.5K |
| Jun 1, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 14,838 | $1.55 | $23.0K |
| May 29, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 16,164 | $1.57 | $25.4K |
| May 21, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 30,882 | $1.69 | $52.2K |
| May 20, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 51,056 | $1.56 | $79.6K |
| May 19, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 68,551 | $1.60 | $109.7K |
10 SEC filing reports analyzed. Sentiment: 2 bullish, 5 bearish, 1 mixed, 2 neutral. Avg impact: 6.6/10.
BULLISH
CLUSTER
7/10
Two 10% owners (Vivo Opportunity, LLC and ADAR1 Capital Management, LLC) purchased a combined $189K
Jun 11, 2026
NEUTRAL
8-K
4/10
InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, closing a
Jun 10, 2026
MIXED
425
7/10
InMed Pharmaceuticals (INM) entered into a definitive reverse merger agreement with Mentari Therapeu
May 19, 2026
BULLISH
8-K
8/10
InMed Pharmaceuticals (INM) entered into a definitive agreement to acquire Mentari Therapeutics via
May 19, 2026
BEARISH
8-K
7/10
InMed Pharmaceuticals amended preferred investment options held by Armistice Capital, reducing the e
May 19, 2026
BEARISH
8-K
8/10
InMed Pharmaceuticals amended preferred investment options (warrants) held by Sabby and H.C. Wainwri
Apr 27, 2026
NEUTRAL
8-K
3/10
InMed Pharmaceuticals filed a prospectus supplement to its shelf registration statement to sell up t
Apr 3, 2026
BEARISH
424B5
8/10
InMed Pharmaceuticals is conducting an at-the-market offering of up to $1.2 million in common shares
Apr 3, 2026
BEARISH
EFFECT
7/10
InMed Pharmaceuticals' S-3 shelf registration has become effective, allowing the company to raise up
Mar 31, 2026
BEARISH
S-3
7/10
InMed Pharmaceuticals has filed an S-3 shelf registration statement allowing it to raise up to $50 m
Mar 20, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 0% buy across 8 analysts — 0 strong buy, 0 buy, 3 hold, 4 sell, 1 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Feb 1, 2023 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Jan 1, 2023 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Dec 1, 2022 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Nov 1, 2022 | 0 | 0 | 3 | 4 | 1 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 20, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| May 20, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 19, 2026
short_volume
Short Volume: INM — 55.1% short (17.5M / 31.8M)
Short: 17,504,441 | Exempt: 201,281 | TRF Vol: 31,780,457 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
INM Q3 2026 Earnings Scheduled — 2026-05-11